Form 4: Foghorn Therapeutics Director Reports Stock Option Grant

Michael Mendelsohn, a Director at Foghorn Therapeutics Inc., reported the acquisition of stock options.

Summary

• Michael Mendelsohn, a Director at Foghorn Therapeutics Inc. (FHTX), has reported the acquisition of 28,000 stock options.
• The options have an exercise price of $4.08 and were granted on June 24, 2026, with an expiration date of June 23, 2036.
• These options vest in full on the first anniversary of the grant date, contingent upon Mr. Mendelsohn's continued service on the board of directors.
• The filing also includes a Limited Power of Attorney appointing Michael LaCascia, Adrian Gottschalk, and Samantha Macina to execute SEC filings on behalf of Mr. Mendelsohn.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard stock option grant to a director, which is a routine event for executive compensation and incentive alignment.

Positives

• Director Michael Mendelsohn has been granted a significant number of stock options (28,000), indicating potential future equity participation.
• The stock options have a long expiration date (June 23, 2036), providing a substantial period for potential value appreciation.
• The vesting schedule is tied to continued service, aligning the director's incentives with the company's long-term success.

Risks

• The value of the stock options is contingent on the future performance of Foghorn Therapeutics' stock price.
• Continued service on the board is required for vesting, meaning any departure before the vesting date would result in forfeiture of the options.

Future Outlook

The future outlook for the stock options is dependent on the company's performance and stock price appreciation, with full vesting occurring on June 24, 2027, assuming continued service.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with shareholder value creation and long-term company growth.

Corporate Governance

Stakeholder Impact

• Shareholders: The stock option grant aligns director incentives with shareholder interests, potentially leading to decisions that enhance company value.
• Employees: While not directly impacting employees, such grants are part of a broader compensation strategy that can influence overall company morale and retention.
• Management: Reinforces the alignment between the board and management's focus on long-term company success.

Next Steps

• Michael Mendelsohn must continue to serve on the board of directors until June 24, 2027, for the stock options to fully vest.
• The company's performance will determine the ultimate value of the vested stock options.

Key Dates

Keywords

Foghorn Therapeutics, FHTX, Form 4, Stock Options, Director, SEC Filing, Beneficial Ownership, Vesting, Michael Mendelsohn